ELI LILLY & CO (LLY)       339.08  +8.38 (+2.53%)

339.08  +8.38 (+2.53%)

US5324571083 - Common Stock - After market: 338.05 -1.03 (-0.3%)

ELI LILLY & CO339.08

NYSE:LLY (2/3/2023, 7:04:00 PM)+8.38 (+2.53%)

After market: 338.05 -1.03 (-0.3%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 02-02 2023-02-02/amc Earnings (Next) 04-27 2023-04-27/amc
Ins Owners 10.55% Inst Owners 79.42%
Market Cap 334.71B Shares 987.12M
PE 39.94 Fwd PE 36.7
Dividend Yield 1.31% Analysts 80
IPO 07-09 1970-07-09

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

LLY Daily chart

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. The company maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Company Info

ELI LILLY & CO

Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr

Indianapolis INDIANA 46285

P: 13172762000.0

CEO: David A. Ricks

Employees: 35000

Website: https://www.lilly.com/

LLY News

News Image2 days ago - Investor's Business DailyMarket Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review

The major indexes continued to run despite mixed-to-weak earnings.

News Image2 days ago - Eli Lilly and CompanyLilly to Participate in Guggenheim Oncology Conference

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023. Jacob Van Naarden,...

News Image2 days ago - The Motley FoolEli Lilly (LLY) Q4 2022 Earnings Call Transcript

LLY earnings call for the period ending December 31, 2022.

News Image2 days ago - Yahoo FinanceCOVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst

Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.

News Image2 days ago - Barron'sLilly and Novo Stock Sold Off. Don't Blame Their Diet Drugs.

The drugs allowed patients to lose as much of 20% of their weight in clinical trials.

News Image3 days ago - ChartmillThese S&P500 stocks are moving in today's session

Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top S&P500 gainers and losers in today's session.

LLY Twits

Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example